Although significant success has been achieved with new generation hormonal therapies in prostate cancer, it has been shown that better results can be achieved in combination with newly developed PART Inhibitor drugs. Therefore, effective treatment options can be determined with comprehensive genetic analysis, especially BRCA mutation. In addition, international guidelines recommend that every patient diagnosed with prostate cancer, regardless of age, should undergo BRCA mutation analysis.